Cercano Management LLC Has $28.72 Million Position in Progyny, Inc. (NASDAQ:PGNY)

Cercano Management LLC lifted its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 8.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 772,339 shares of the company's stock after buying an additional 62,983 shares during the period. Progyny makes up about 0.9% of Cercano Management LLC's investment portfolio, making the stock its 28th largest holding. Cercano Management LLC owned about 0.81% of Progyny worth $28,716,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. State of New Jersey Common Pension Fund D boosted its position in shares of Progyny by 14.8% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 73,864 shares of the company's stock worth $2,746,000 after buying an additional 9,547 shares during the period. Yousif Capital Management LLC raised its holdings in Progyny by 4.4% during the fourth quarter. Yousif Capital Management LLC now owns 40,481 shares of the company's stock worth $1,505,000 after purchasing an additional 1,710 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in Progyny by 9.3% in the fourth quarter. Parkside Financial Bank & Trust now owns 3,096 shares of the company's stock worth $115,000 after purchasing an additional 264 shares during the period. New York State Common Retirement Fund boosted its stake in Progyny by 18.5% during the 4th quarter. New York State Common Retirement Fund now owns 256,344 shares of the company's stock valued at $9,531,000 after purchasing an additional 39,934 shares in the last quarter. Finally, Cetera Trust Company N.A bought a new position in Progyny during the 4th quarter valued at $183,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

PGNY has been the topic of several research reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $48.00 price target on shares of Progyny in a research report on Wednesday, February 28th. KeyCorp lowered their price objective on shares of Progyny from $45.00 to $43.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 28th. Barclays started coverage on shares of Progyny in a research note on Wednesday, January 3rd. They set an "overweight" rating and a $48.00 target price for the company. Truist Financial restated a "buy" rating and set a $46.00 target price on shares of Progyny in a report on Wednesday, April 17th. Finally, Leerink Partnrs restated an "outperform" rating on shares of Progyny in a report on Monday, February 26th. Ten equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Progyny presently has a consensus rating of "Buy" and a consensus price target of $48.30.

Progyny Price Performance

Progyny stock traded down $0.46 during midday trading on Friday, reaching $32.04. The stock had a trading volume of 583,458 shares, compared to its average volume of 653,672. The firm's fifty day simple moving average is $35.84 and its two-hundred day simple moving average is $35.64. Progyny, Inc. has a twelve month low of $29.44 and a twelve month high of $44.95. The firm has a market cap of $3.08 billion, a price-to-earnings ratio of 51.68, a PEG ratio of 1.32 and a beta of 1.48.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.13 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.04. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The firm had revenue of $269.94 million during the quarter, compared to analyst estimates of $274.08 million. During the same quarter last year, the business posted $0.03 EPS. The company's revenue was up 26.0% on a year-over-year basis. As a group, sell-side analysts predict that Progyny, Inc. will post 0.7 EPS for the current fiscal year.

Insider Buying and Selling

In other Progyny news, President Michael E. Sturmer sold 2,260 shares of Progyny stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $40.00, for a total transaction of $90,400.00. Following the completion of the sale, the president now owns 158,532 shares of the company's stock, valued at approximately $6,341,280. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Progyny news, Chairman David J. Schlanger sold 20,000 shares of Progyny stock in a transaction on Monday, February 5th. The shares were sold at an average price of $38.50, for a total transaction of $770,000.00. Following the completion of the sale, the chairman now owns 86,312 shares of the company's stock, valued at approximately $3,323,012. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, President Michael E. Sturmer sold 2,260 shares of Progyny stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $40.00, for a total transaction of $90,400.00. Following the sale, the president now directly owns 158,532 shares of the company's stock, valued at approximately $6,341,280. The disclosure for this sale can be found here. In the last 90 days, insiders sold 120,515 shares of company stock valued at $4,570,131. Company insiders own 12.30% of the company's stock.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.